Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed is attractive because its FDA-cleared, AI-enabled aprevo platform is differentiated by patient-specific implants, lower revision rates, and stronger facility economics, with a 2-year study showing a 4.3% revision rate versus 16.6% for stock implants. Its commercial momentum appears durable, as revenue has compounded at a 92% CAGR from 2023 to 2025, active surgeons grew to 284 as of 1Q26, and FY26 revenue is expected at roughly $72M to $77M with gross margin in the mid- to high-70s. The company also has a favorable operating model, with $97 million in cash as of 1Q26, minimal capital intensity, and a clear path to higher adoption from Cervical launches, reimbursement tailwinds, and continued surgeon onboarding.

Carlsmed is a high-growth but still unprofitable medtech story whose valuation depends on sustained surgeon adoption, premium reimbursement, and continued beats-and-raises, leaving it vulnerable if growth slows or hospitals delay approvals. The company’s own modeled downside includes slower uptake, lower spine market growth, faster ASP erosion, later cervical entry, and higher operating expenses, while FY26 still implies $75.0M-$76.9M in revenue against roughly $100.5M-$102.9M of opex and $33.7M-$44.5M of adjusted EBITDA loss. With reimbursement changes potentially pressuring pricing, a concentrated customer base of about 293 surgeons in 1Q26, and consensus still negative EBITDA through 2028, the path to profitability looks uncertain and supports a bearish outlook.